Pharmaceuticals and healthcare industry monitor Bioethics International has published its Good Pharma Scorecard, ranking pharmaceutical companies on their clinical trial transparency.
The not-for-profit group describes itself as being “dedicated to raising the bar on ethics, trustworthiness, and patient-centricity in pharma.”
The annual ranking evaluates clinical trial registration, results reporting, clinical study report synopsis sharing, and journal article publication rates for new drugs.
US healthcare giant Johnson & Johnson (NYSE: JNJ) and French pharma major Sanofi (Euronext: SAN) came in joint leaders.
AbbVie (NYSE: ABBV), Celgene (Nasdaq: CELG), Merck & Co (NYSE: MRK) and AstraZeneca (LSE: AZN) all scored at or above the industry median.
The group said that “meaningful progress has been made on several key metrics since the first Scorecard was released in 2015,” noting that public availability of results for trials increased from a median of 87% to 96%.
Founder Jennifer Miller said: “This year’s Scorecard shows clear corporate leaders in clinical trial transparency and industry improvement on several metrics.”
“We hope this improvement continues year after year, because clinical trial transparency is critical for advancing innovation, respect for trial participants, and patient health.”
